Vanderbilt researchers have discovered specific morphogens that can promote differentiation of embryonic stem cells to cardiomyocytes. In addition when these morphogens are added to stem cells during differentiation a 10 to 20 fold increase is seen in cardiomyocyte formation. Thus addition of such morphogens may prove to be a valid therapy for cardiac repair and regeneration.
Vanderbilt researchers have identified compounds that selectively differentiate stem cells into cardiomyocytes by perturbing key pathways. Medicinal chemistry is currently underway to develop lead compounds that maybe used for the treatment of damaged cardiac muscle.
This is a genetically engineered mouse ES stem cell line marking cardiomyocytes with red fluorescent protein (RFP). These cells have been used in high-throughput screens by Vanderbilt researchers for pro-cardiogenic factors. In addition the construct used in this cell line could be used to mark the cardiac progeny of transplanted stem cells, generate stable human ES cell lines, or engineer iPS for cardiac lineage studies.
Dr. Piston's group has generated a variant of the enhanced cyan fluorescent protein (ECFP) that has improved brightness, more resistance to photo-bleaching and a fluorescence lifetime that is best fit by a single exponential.
Angioedema is a life-threatening and unpredictable side effect of angiotensin converting enzyme (ACE) inhibitors and ACE/Neutral endopeptidase (NEP) inhibitors, drugs aimed at reducing cardiovascular mortality associated with a variety of disease states. This technology permits the identification of individuals at risk for developing this angioedemic condition as a result of taking ACE inhibitors or NEP inhibitors. The patents and patent applications claim biological markers, diagnostic methods and kits.
A method of altering specificity of cyclooxygenase-inhibiting compounds that have a COOH moiety by changing the various COOH containing compounds, such as indomethacin, into ester derivatives or into secondary amide derivatives.
The c-Myc oncogene is bound by p19Arf, which inhibits c-Myc's ability to transform cells while augmenting apoptosis. This provides the basis for screening assays that examine the ability of various candidate substances to promote p19Arf interactions, or to substitute therefor.
The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
The tissue of the human body is separated by planes separated by minimal fluid, and it is often desirable to enter into the space between these planes to perform procedures including delivery or removal of fluid/therapeutics. Accurately and harmlessly placing catheters within these planes is very difficult because of the very close proximity of the tissues -- often within 1mm. The Transductive Access Catheter System solves these problems by allowing the operator to insert a shallow beveled needle into the space of interest using a hollow inner catheter that is filled with saline to probe much like a micro water hammer to detect difference in resistance to flow at the tip of the catheter. The primary competing technology uses suction to pull on the outer tissue which increases the target space volume at the catheter; however this has limitations of tissue rigidity and thickness (PerDUCER, Comedicus). Due to the versatility across disciplines, a wide variety of applications for this catheter exist, which include: Pericardial Space Infusion or Drainage, Pleural Space Infusion or Drainage, Subdural and Epidural Infusion, and Intraocular Fluid Space Infusion or Drainage.